"Isthmin Protein Therapeutics for the Treatment of Non-Alcoholic Fatty Liver Disease" in Patent Application Approval Process (USPTO 20240342244).

The patent application titled "Isthmin Protein Therapeutics for the Treatment of Non-Alcoholic Fatty Liver Disease" discusses the potential therapeutic use of ISM1 protein in addressing glucose and lipid-associated disorders, particularly non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). The inventors propose that ISM1 protein can dissociate glucose uptake from lipid synthesis, potentially improving diabetes by decreasing insulin resistance and ameliorating hepatic steatosis. The application suggests that ISM1 protein could be administered to individuals to simultaneously treat hyperglycemia and hyperlipidemia, offering a new avenue for addressing metabolic syndrome. [Extracted from the article]